IOVA
NASDAQIovance Biotherapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks63+186%
2025-12-282026-06-21
Mix3390d
- Insider14(42%)
- SEC Filings9(27%)
- Other8(24%)
- Earnings2(6%)
Latest news
25 items- PRIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on June 18, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees. The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Compa
- INSIDERSEC Form 4 filed by Director Weiser Michael4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Director Dukes Iain D.4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Director Countouriotis Athena4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Director Maynard Ryan D4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 4 filed by Chief Regulatory Officer Puri Raj K.4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- SECSEC Form S-8 filed by Iovance Biotherapeutics Inc.S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECSEC Form S-8 filed by Iovance Biotherapeutics Inc.S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECSEC Form S-3ASR filed by Iovance Biotherapeutics Inc.S-3ASR - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- INSIDERInterim CEO & General Counsel Vogt Frederick G converted options into 15,625 shares and covered exercise/tax liability with 6,638 shares, increasing direct ownership by 2% to 562,492 units (SEC Form 4) (tax liability)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Medical Officer Graf Finckenstein Friedrich converted options into 7,813 shares and covered exercise/tax liability with 3,976 shares, increasing direct ownership by 3% to 140,111 units (SEC Form 4) (for withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Regulatory Officer Puri Raj K. converted options into 9,766 shares and covered exercise/tax liability with 3,843 shares, increasing direct ownership by 2% to 248,114 units (SEC Form 4) to cover withholding tax4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Operating Officer Bilinsky Igor converted options into 7,813 shares and covered exercise/tax liability with 3,976 shares, increasing direct ownership by 3% to 133,920 units (SEC Form 4) (for withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- PRThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, Inc. (NASDAQ:GTBP) has now advanced three TriKE® candidates into the clinic over time --- GTB-3550, GTB-3650 and GTB-5550 --- though its curr
- INSIDERInterim CEO & General Counsel Vogt Frederick G converted options into 41,668 shares and covered exercise/tax liability with 17,701 shares, increasing direct ownership by 5% to 553,505 units (SEC Form 4) (withholding obligation)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Regulatory Officer Puri Raj K. covered exercise/tax liability with 2,508 shares and converted options into 5,469 shares, increasing direct ownership by 1% to 242,191 units (SEC Form 4) (tax liability)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Medical Officer Graf Finckenstein Friedrich covered exercise/tax liability with 4,473 shares and converted options into 8,790 shares, increasing direct ownership by 3% to 136,274 units (SEC Form 4) (withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Operating Officer Bilinsky Igor converted options into 8,790 shares and covered exercise/tax liability with 4,473 shares, increasing direct ownership by 3% to 130,083 units (SEC Form 4) (tax withholding)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- PRIovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced allowance to proceed from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy. The Phase 1/2 trial will begin enrolling in the second half of 2026 to investigate the
- PRIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 21, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance's common stock to thirteen new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company's co
- PRIovance Biotherapeutics to Present at Upcoming ConferenceSAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Fred Vogt, PhD, Interim CEO, President and General Counsel, and Corleen Roche, Chief Financial Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York, NY. The live and archived webcast will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, In
- INSIDERChief Commercial Officer Kirby Daniel Gordon converted options into 10,000 shares and covered exercise/tax liability with 2,435 shares, increasing direct ownership by 5% to 146,946 units (SEC Form 4) (tax withholding)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Iovance Biotherapeutics Inc.SCHEDULE 13G - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
IOVA FAQ
6 questionsWhat does Iovance Biotherapeutics Inc. do?
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance...Where does IOVA stock trade?
Iovance Biotherapeutics Inc. (IOVA) is listed on NASDAQ.What sector and industry is IOVA in?
Iovance Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about IOVA?
Iovance Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $500.00 price target on 2026-02-25.What companies are similar to IOVA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IOVA side-by-side with any of them on Quantisnow.How can I track IOVA on Quantisnow?
Quantisnow aggregates Iovance Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IOVA to receive live email and push alerts on every new disclosure.